Patritumab

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].

Product Specifications

CAS Number

[1262787-83-6]

Product Name Alternative

Human Anti-ERBB3 Recombinant Antibody

UNSPSC

12352203

Target

Akt; EGFR; ERK; PARP; Survivin

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/patritumab.html

Purity

99.28

Solubility

10 mM in DMSO

Smiles

[Patritumab]

Molecular Weight

(146.86 kDa)

References & Citations

[1]Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5 (23) :11847-56.